65,437 trials
Pancreatic Cancer Non-resectable
Primary: Overall Survival — 17.25; 17.94 months — p=0.5487
Self Harm · Depression · Emotion Dysregulation
Primary: Columbia Suicide Severity Rating Scale (CSSRS) Suicide Ideation — 20; 13; 16; 8 Participants
Behavioral Changes
Primary: Sexual/Reproductive Health Behaviors — 24; 17 Participants
Bell's Palsy · Facial Nerve Paresis
Primary: Facial Nerve Recovery — 7; 81.56 Days
End Stage Renal Disease
Primary: Mortality — 1756; 1856 participants
Prostate Cancer · Cholelithiases · Cholecystitis
Primary: Completion Rate — 20; 19 Participants
Healthy
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 3; 1; 3; 2 Participants
Hysterotomy
Primary: Quantitative Blood Loss — 641.8; 596.5 mL
Oral Mucositis
Primary: Duration of Severe Oral Mucositis (SOM) — 22.9; 27.7; 35.2; 37.8 Days
Liver Cancer
Primary: The Safety of Hypofractionated Stereotactic Radiotherapy in Patients With Advanced Hepatocellular Carcinoma — 0; 0; 1; 3 Participants
Tobacco Use Disorder · Smoking Cessation
Primary: Point Prevalence Abstinence at the End of 12 Weeks — 12; 6; 5; 9 Participants
Influenza
Primary: Percent of Subjects Achieving Seroconversion Increased More Than 4-fold Versus Baseline for Antigens: Influenza Virus Type А - H1N1, Influenza Virus Type А - H3N2…
Preterm Birth
Primary: Number of Eligible Participants Who Are Successfully Recruited and Attend at Least One Group Session — 20 Participants
Fabry Disease
Primary: Total Time Spent by Healthcare Professionals (HCPs) in the Preparation/Administration of a Single Dose of ERT in Patients With Fabry Disease — 151.9 minutes
Bacterial Infections
Primary: Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline — 72; 35 Participants